NMDA receptor pathways as drug targets - PubMed

Affiliations

• PMID: 12403981
• DOI: 10.1038/nn936

Review

NMDA receptor pathways as drug targets

John A Kemp et al. Nat Neurosci. 2002 Nov.

Abstract

Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease, for which effective therapies are still lacking.

Similar articles

• Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease.

  Benarroch EE. Benarroch EE. Neurology. 2008 Mar 18;70(12):964-8. doi: 10.1212/01.wnl.0000306315.03021.2a. Neurology. 2008. PMID: 18347319 Review. No abstract available.

• 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.

  Karanian DA, Baude AS, Brown QB, Parsons CG, Bahr BA. Karanian DA, et al. Hippocampus. 2006;16(10):834-42. doi: 10.1002/hipo.20214. Hippocampus. 2006. PMID: 16897723

• Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.

  Ritzén A, Mathiesen JM, Thomsen C. Ritzén A, et al. Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):202-13. doi: 10.1111/j.1742-7843.2005.pto_156.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 16176554 Review.

• Mechanism of action of memantine.

  Johnson JW, Kotermanski SE. Johnson JW, et al. Curr Opin Pharmacol. 2006 Feb;6(1):61-7. doi: 10.1016/j.coph.2005.09.007. Epub 2005 Dec 20. Curr Opin Pharmacol. 2006. PMID: 16368266 Review.

• The chemical biology of clinically tolerated NMDA receptor antagonists.

  Chen HS, Lipton SA. Chen HS, et al. J Neurochem. 2006 Jun;97(6):1611-26. doi: 10.1111/j.1471-4159.2006.03991.x. J Neurochem. 2006. PMID: 16805772 Review.

Cited by

• Glutamatergic stimulation induces GluN2B translation by the nitric oxide-Heme-Regulated eIF2α kinase in cortical neurons.

  Ramos-Fernández E, Tajes M, Ill-Raga G, Vargas L, Busquets-García A, Bosch-Morató M, Guivernau B, Valls-Comamala V, Gomis M, Grau C, Fandos C, Rosen MD, Rabinowitz MH, Inestrosa N, Maldonado R, Altafaj X, Ozaita A, Alvarez A, Vicente R, Valverde MA, Muñoz FJ. Ramos-Fernández E, et al. Oncotarget. 2016 Sep 13;7(37):58876-58892. doi: 10.18632/oncotarget.11417. Oncotarget. 2016. PMID: 27557499 Free PMC article.

• Oligodendrocyte N-methyl-D-aspartate receptor signaling: insights into its functions.

  Cao N, Yao ZX. Cao N, et al. Mol Neurobiol. 2013 Apr;47(2):845-56. doi: 10.1007/s12035-013-8408-8. Epub 2013 Jan 24. Mol Neurobiol. 2013. PMID: 23345133 Review.

• Blood-Brain Barrier Disintegration in Growth-Restricted Fetuses with Brain Sparing Effect.

  Misan N, Michalak S, Kapska K, Osztynowicz K, Ropacka-Lesiak M. Misan N, et al. Int J Mol Sci. 2022 Oct 15;23(20):12349. doi: 10.3390/ijms232012349. Int J Mol Sci. 2022. PMID: 36293204 Free PMC article.

• NMDA receptor regulation by D-serine: new findings and perspectives.

  Wolosker H. Wolosker H. Mol Neurobiol. 2007 Oct;36(2):152-64. doi: 10.1007/s12035-007-0038-6. Epub 2007 Sep 12. Mol Neurobiol. 2007. PMID: 17952659 Review.

• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  Rogawski MA, Wenk GL. Rogawski MA, et al. CNS Drug Rev. 2003 Fall;9(3):275-308. doi: 10.1111/j.1527-3458.2003.tb00254.x. CNS Drug Rev. 2003. PMID: 14530799 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information